Federated Hermes
DYN icon

Federated Hermes’s Dyne Therapeutics DYN Stock Holding History

Federated Hermes’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-464,797
Closed -$9.09M – 2089
2025
Q4 		$9.09M Buy
+464,797
New +$8.8M 0.02% 650
2025
Q1 		– Sell
-1,056,241
Closed -$24.9M – 2094
2024
Q4 		$24.9M Sell
1,056,241
-160,929
-13% -$4.76M 0.05% 372
2024
Q3 		$43.7M Buy
1,217,170
+2,058
+0.2% +$81.9K 0.1% 260
2024
Q2 		$42.9M Buy
1,215,112
+114,888
+10% +$3.34M 0.1% 242
2024
Q1 		$31.2M Buy
1,100,224
+725,224
+193% +$16.4M 0.07% 318
2023
Q4 		$4.99M Buy
+375,000
New +$3.66M 0.01% 725
2023
Q3 		– Sell
-82,400
Closed -$927K – 2127
2023
Q2 		$927K Sell
82,400
-180,796
-69% -$2.13M ﹤0.01% 1160
2023
Q1 		$3.03M Buy
263,196
+262,960
+111,424% +$3.42M 0.01% 830
2022
Q4 		$2.73K Buy
+236
New +$2.73K ﹤0.01% 1985
2022
Q1 		– Sell
-341
Closed -$4K – 2226
2021
Q4 		$4K Sell
341
-433
-56% -$6.08K ﹤0.01% 2009
2021
Q3 		$13K Buy
+774
New +$13.7K ﹤0.01% 1963

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Federated Hermes's DYN Position: Q1 2026 in Review

Federated Hermes sold out of Dyne Therapeutics (DYN) in Q1 2026, closing a stake of 464,797 shares — an estimated $9.09M sold.

Federated Hermes first reported a position in DYN in Q3 2021 and held it in 11 quarters. The position peaked at $43.7M in Q3 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Federated Hermes reported no remaining Dyne Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Federated Hermes sold 464,797 Dyne Therapeutics shares in Q1 2026, an estimated $9.09M.
  • Federated Hermes first reported a position in Dyne Therapeutics in Q3 2021 and held it in 11 quarters.
  • Federated Hermes's Dyne Therapeutics position peaked at $43.7M in Q3 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.